Hain rebuked by NASDAQ
This article was originally published in The Rose Sheet
Executive Summary
Staff determination letter sent by NASDAQ Nov. 14 states that Hain Celestials is not in compliance with filing requirements for continued listing due to its failure to timely file Form 10-Q for the fiscal period ended Sept. 30, 2007, firm announces Nov. 16. An independent review of the company's stock option practices, launched last September, is "substantially complete" but has delayed the filing of the 10-Q, as well as its Annual Report on Form 10-K for the year ended June 30, 2007 (1"The Rose Sheet" Sept. 24, 2007, In Brief). Hain shares remain listed on NASDAQ pending a decision from its Listing Qualifications Panel, with which the company met Oct. 31. Any adjustments that have been identified in its review will not affect the company's previously released results of operations for the fiscal year or quarter in question, the firm says...
You may also be interested in...
Hain filing delay
Hain Celestials has requested a hearing before a NASDAQ Listing Qualifications Panel to request continued listing on the stock market, the firm announces Sept. 20. On Sept. 14, the natural-food and personal-care company received a staff determination letter indicating that Hain is not in compliance with NASDAQ filing requirements due to a delay in filing Form 10-K. Hain shares will continue to be listed on NASDAQ pending a decision by the Listing Qualifications Panel. Hain says it is conducting a review of its stock-option practices under the direction of "a group of independent investors" and independent legal counsel. "The timing of that completion has resulted in a delay in finalizing the company's annual report on form 10-K," Hain says. Company notes that the results of the review and any changes recommended by reviewers will not affect its Q4 and FY 2007 results...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.